Thermo Fisher Scientific PAI1 Monoclonal Antibody (MA-33H1F7)

Applications

Tested Dilution

Publications

Western Blot (WB)

1:50

-

Immunocytochemistry (ICC/IF)

1:200

-

ELISA (ELISA)

1:50

-

Functional Assay (Functional)

1:50

-

Product Specifications

Species Reactivity

Human, Mouse, Rat

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

MA-33H1F7

Immunogen

Human PAI-1.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.1 mg/mL

Purification

Protein G

Storage buffer

PBS with 0.1% BSA

Contains

no preservative

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2186871

Product Specific Information

MA1-40224 detects PAI-1 from human, rat, mouse and rabbit samples.

MA1-40224 has been successfully used in ELISA, functional studies and Western blot applications.

The MA1-40224 immunogen is human PAI-1.

Endotoxin <24 EU/mg.

The epitope (hF epitope) of MA1-40224 is predominantly composed of three residues (Lys154/Glu130/Arg131), positioned virtually linearly in the three-dimensional structure. The epitope of the antibody does not cover the complete alpha-helix F and turn connecting alpha-helix F and beta-strand s3A, but is restricted to the hinge region between alpha-helix F and the main part of the PAI-1 molecule. MA1-40224 is a ‘switching` antibody, capable of inducing a non-inhibitory substrate form of PAI-1. It was shown to inhibit PAI-1 in a dose dependent manner.

Target Information

PAI1 (plasminogen activator inhibitor 1) belongs to serine protease inhibitor superfamily, and is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA). Platelets are the main source of the circulating PAI11, but it is synthesized and secreted by many tissue and cell types, including fibroblasts, smooth muscle cells, endothelial cells, hepatocytes, and inflammatory cells. Expression of PAI11 can be regulated at the transcriptional level by many factors including growth factors, cytokines, hormones, inflammatory factors, glucose or lipid metabolites, vascular tone regulating factors, chemicals, and other environmental or physical factors. PAI1 is present at increased levels in various disease states, and has been linked to an increased occurrence of thrombosis in obesity, thrombophilia and the metabolic syndrome. Defects in PAI-1 are characterized by abnormal bleeding. PAI1 mediates inhibition of fibrinolysis by inhibiting the activity of plasminogen activator, and may promote neuronal survival. Other defects in PAI1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency). Alternatively spliced transcript variants encoding different isoforms of PAI1 have been found.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.